Screening detects ovarian cancer using neighboring cells

Pioneering biophotonics technology developed at Northwestern University is the first screening method to detect the early presence of ovarian cancer in humans by examining cells easily brushed from the neighboring cervix or uterus, not the ovaries themselves.

A research team from Northwestern and NorthShore University HealthSystem (NorthShore) conducted an clinical study at NorthShore. Using partial wave spectroscopic (PWS) microscopy, they saw diagnostic changes in cells taken from the cervix or uterus of patients with ovarian cancer even though the cells looked normal under a microscope.

The results have the potential to translate into a minimally invasive early detection method using cells collected by a swab, exactly like a Pap smear. No reliable early detection method for ovarian cancer currently exists.

In previous Northwestern-NorthShore studies, the PWS technique has shown promising results in the of colon, pancreatic and lung cancers using cells from neighboring organs. If commercialized, PWS could be in clinical use for one or more cancers in approximately five years.

The ovarian cancer study was published this month by the International Journal of Cancer.

PWS uses light scattering to examine the architecture of cells at the and can detect profound changes that are the earliest known signs of . These changes can be seen in cells far from the tumor site or even before a tumor forms.

"We were surprised to discover we could see diagnostic changes in cells taken from the endocervix in patients who had ovarian cancer," said Vadim Backman, who developed PWS at Northwestern. "The advantage of nanocytology—and why we are so excited about it—is we don't need to wait for a tumor to develop to detect cancer."

Backman is a professor of biomedical engineering at the McCormick School of Engineering and Applied Science. He and his longtime collaborator, Hemant K. Roy, M.D., formerly of NorthShore, have been working together for more than a decade and conducting clinical trials of PWS at NorthShore for four years. Backman and Roy both are authors of the paper.

"The changes we have seen in cells have been identical, no matter which organ we are studying," Backman said. "We have stumbled upon a universal cell physiology that can help us detect difficult cancers early. If the changes are so universal, they must be very important."

Ovarian cancer, which ranks fifth in cancer fatalities among American women, usually goes undetected until it has spread elsewhere. The cancer is difficult to treat at this late stage and often is fatal.

"This intriguing finding may represent a breakthrough that would allow personalization of screening strategies for ovarian cancer via a minimally intrusive test that could be coupled to the ," Roy said.

At the time of the ovarian cancer study, Roy was director of gastroenterology research at NorthShore and worked with Jean A. Hurteau, M.D., a gynecological oncologist at NorthShore. (Hurteau is an author of the paper.) Roy is now chief of the section of gastroenterology at Boston University School of Medicine and Boston Medical Center.

The study included a total of 26 individuals. For cells taken from the endometrium (part of the uterus), there were 26 patients (11 with ovarian cancer and 15 controls); for cells taken from the endocervix, there were 23 patients (10 with ovarian cancer and 13 controls). The small size of the study reflects the difficulty in recruiting ovarian cancer patients.

Cells were placed on slides and then examined using PWS. The results showed a significant increase in the disorder of the nanoarchitecture of epithelial cells obtained from cancer patients compared to controls for both the endometrium and endocervix studies.

The cells for the ovarian cancer study were taken from the cervix and uterus. For the earlier lung , cells were brushed from the cheek. For the colon, cells came from the rectum, and for the pancreas, cells came from the duodenum. Cells from these neighboring organs showed changes at the nanoscale when cancer was present.

PWS can detect cell features as small as 20 nanometers, uncovering differences in cells that appear normal using standard microscopy techniques. PWS measures the disorder strength of the nanoscale organization of the cell, which is a strong marker for the presence of cancer in the organ or in a nearby organ.

The PWS-based test makes use of the "field effect," a biological phenomenon in which located some distance from the malignant or pre-malignant tumor undergo molecular and other changes.

More information: The paper is titled "Insights into the field carcinogenesis of ovarian cancer based on the nanocytology of endocervical and endometrial epithelial cells." The paper is available at onlinelibrary.wiley.com/doi/10… 2/ijc.28122/abstract

Related Stories

'Normal' cells far from cancer give nanosignals of trouble

Jul 07, 2009

(PhysOrg.com) -- A new Northwestern University-led study of human colon, pancreatic and lung cells is the first to report that cancer cells and their non-cancerous cell neighbors, although quite different under the microscope, ...

Early lung cancer detection

Oct 05, 2010

Researchers from Northwestern University and NorthShore University HealthSystem (NorthShore) have developed a method to detect early signs of lung cancer by examining cheek cells in humans using pioneering biophotonics technology.

Cheek swab may detect lung cancer

Oct 07, 2010

Early detection is critical for improving cancer survival rates. Yet, one of the deadliest cancers in the United States, lung cancer, is notoriously difficult to detect in its early stages.

Breakthrough in early cancer detection

Jan 10, 2012

Cape Cod-TV correspondent Melissa Chartrand went into the hospital three years ago to undergo a hysterectomy, a common procedure that was supposed to eliminate her abdominal pains. But for Melissa, a far more serious pain ...

Recommended for you

Video: Is that double mastectomy really necessary?

Oct 24, 2014

When Angeline Vuong, 27,was diagnosed with cancer in one breast earlier this year, her first reaction was "A DOUBLE MASTECTOMY. NOW. " Turns out, she's far from alone: a recent JAMA study of 190,000 breast cancer cases in ...

User comments